Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
about
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunizationEnhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cellsA novel proteoliposomal vaccine induces antitumor immunity against follicular lymphomaEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesTreatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development.Profile of Ronald Levy. Interview by Phillip DowneyGeneration in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysatePlacebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphomaPhase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.Active idiotypic vaccination versus control immunotherapy for follicular lymphomaGenetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphomaInhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in miceIdiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survivalTumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells.Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plantsIdiotype vaccines for lymphoma: Potential factors predicting the induction of immune responses.Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy.Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines.A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide.DNA vaccines to attack cancerIdiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivoA physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vesselsElicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.Therapeutic cancer vaccines: the latest advancement in targeted therapy.Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphomaWhole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells.Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccinesLymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.Active immunotherapy: current state of the art in vaccine approaches for NHLHybridoma-Derived Idiotype Vaccine for Lymphoma: Approval Must Wait.Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody.Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells
P2860
Q24655648-A46AE217-5AA9-4D15-834F-FFB1DF2606B6Q24658494-BA8F1AD4-019B-46D4-AEC6-0A4FE9250E72Q24681501-32ADEB84-863B-4720-82D2-008EDB90747DQ27008070-67566C0F-8CC8-4376-95E4-5FDBA19444BFQ27693252-F0B289FB-7318-4BAB-B7FE-34AD2338113CQ28314974-2CF5D7BD-73C5-4FDA-8E5D-EB2771177C71Q28362580-2116DF08-D656-4765-B6AD-A767E64424C8Q30419228-4EE850D5-1127-450B-83AF-BC6C24219B47Q33386521-533DD085-45CB-4BB3-9C65-A1C8FC2E7C1FQ33691505-C773FE52-AA37-4FA6-8DC7-69EAF1886226Q33814247-207D1C9D-9231-4C42-969E-DE1E7F3DA4CEQ33911670-3C9FCF86-5FBC-4793-84B4-5913A4E934DEQ33989839-8C04DA2A-700E-4763-BCF5-CC40B5484135Q34011489-DB10B40F-BF83-42DE-BB3F-6FCD7DAADF61Q34038839-6AC6C55C-0952-4CEB-8B64-B1D4F1F29783Q34075717-53526AB2-BE0B-4BD7-A315-3B3502A6B236Q34534544-9ABA8935-5FD8-468D-84C0-745CA2DCDEBFQ34849268-2A809DDD-8F17-417E-BA34-F8196BD6979FQ35113388-6F31A537-F81F-4756-BA0A-B01105F24DA1Q35616042-A4C1D870-1108-4706-A55D-27EE3C37B3E8Q35751104-850F082A-754C-403D-AEBD-D3FF49CF596CQ35839905-BFC95C43-2997-408B-B02C-291351693252Q35848862-578AC397-CCBF-4CAD-82AD-A6A3044713E6Q35855143-CA829389-297C-4AEF-9035-CFA5FBB89610Q35863376-955892D7-9921-4808-BF3B-5B2620E4DEF4Q36407174-A764FF31-6196-477C-A339-111C3F4C5AAFQ36499151-DFD3A361-066E-4AEC-9A47-425D25B9798CQ36649560-2820255A-2A62-4FAA-B1BA-E968038C2239Q36695629-78B879AA-D27C-489A-85F8-8DDF97F85F7CQ36787005-1201418C-8D0E-49F7-B1AA-D32C3FD8DE91Q37083964-7DD553A9-D29C-4B23-90D3-C764EAAE30B1Q37142202-CDF7ABC3-2E8A-404F-858D-CDD5DEBFA1E9Q37237431-F194B93E-7477-4C1C-9AAF-42682EECAD88Q37376663-73857975-D0E1-4B97-B853-5B9AF05FA065Q37401011-D33CA1F1-589B-4608-A4F8-D3C1E294E7BEQ37773301-69A0E43C-6E26-4F44-B492-954F486205D2Q38030484-E073C522-C942-40E6-A7A5-49A105DF1D15Q38974216-E2E059B8-44E6-4D63-A0DB-377029952734Q41008658-6A4CEDB0-D258-434B-A3B8-4F36101A5A26Q41912026-64022E6B-CBC2-4814-8DE4-D954073ACC88
P2860
Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@ast
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@en
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@nl
type
label
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@ast
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@en
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@nl
prefLabel
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@ast
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@en
Tumor-specific idiotype vaccin ...... m results of a clinical trial.
@nl
P2093
P1433
P1476
Tumor-specific idiotype vaccin ...... rm results of a clinical trial
@en
P2093
A Syrengelas
B Taidi-Laskowski
C B Caspar
D Czerwinski
P304
P407
P577
1997-05-01T00:00:00Z